A Phase 3 interventional study of TAK-861 and Placebo in Narcolepsy Type 1, sponsored by Takeda. Completed at 28 sites in 11 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Narcolepsy by Takeda — 4 open to participants now, 6 under way, 2 of them phase 3. Narcolepsy · Takeda.
Among the 16 studies in Narcolepsy by Takeda, this one is the 4th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is one of 3 in phase 3, and was the 11th registered.
158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.
Browse Narcolepsy studies →4 of the 16 studies in Narcolepsy by Takeda are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Australia, China and 4 more countries
Ages 18–70
Takeda · Sites in United States, China, France and 4 more countries
Ages 18–70
Takeda · Sites in United States, Australia, Finland and 9 more countries
Ages 16–70
Takeda
Ages 18–70
By country, each count listing its studies:
Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 4
First in 2017; this study’s year is marked. 2 started in 2024.
This study's enrollment of 105 is above the median of 78 across 114 interventional studies indexed under Narcolepsy.
Median enrollment 95 across the 12 interventional studies, 307 across the 4 observational. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
5 of the studies in Narcolepsy by Takeda that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07363720Phase 3TakedaA Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy | 2026-12-17 |
| NCT06952699TakedaA Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) | 2026-11-30 |
| NCT07299097TakedaEpidemiology of Narcolepsy Type 1 and Type 2 in Spain | 2026-12-31 |
| NCT07903220TakedaA Study About Treatment Use in Adults With Narcolepsy Type 1 (NT1) in Europe and Canada | 2027-09-30 |
| NCT07633301TakedaA Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy) | 2027-11-28 |
Add all 5 to your calendar (.ics) → With an account.
Among the 16 studies in Narcolepsy by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main aim of this study is to learn how effective TAK-861 is in improving excessive sleepiness during the day (called excessive daytime sleepiness or EDS) after 3 months of treatment. Other aims are to learn how effective TAK-861 is in lowering the number of sudden, unexpected attacks of muscle weakness while staying conscious (cataplexy) in a week; to learn the effect TAK-861 has on participants' ability to maintain attention, participant's overall quality of life, the spectrum of narcolepsy symptoms and daily life functions; and to learn about the safety of TAK-861.
The drug being tested in this study is called TAK-861. TAK-861 is being tested to evaluate its efficacy and safety in participants with narcolepsy with cataplexy (narcolepsy type 1 [NT1]).
The study will enroll approximately 93 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups:
The study drug will be administered for 12 weeks. This multi-center trial will be conducted globally.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received oveporexton matching placebo tablets, orally, twice daily (BID) for 12 weeks.
Drug: Placebo
Participants received oveporexton tablets, 2 milligrams (mg), orally, BID for 12 weeks.
Drug: TAK-861
Oral tablet.
TAK-861-matching placebo tablet.
Change From Baseline to Week 12 in Mean Sleep Latency From the Maintenance of Wakefulness Test (MWT) Wake Trials
The MWT evaluates a person's ability to remain awake under soporific conditions for a defined period of time. Because there is no biological measure of wakefulness, wakefulness is measured indirectly by the inability or delayed tendency to fall asleep. This tendency to fall asleep is measured via electroencephalography-derived sleep latency in the MWT. The MWT consists of four 40-minute sessions (trials) done 2 hours apart. Sleep latency in each session was recorded. Participants were required to stay awake in between the four sessions. A positive change from baseline indicates an improvement. The linear MMRM was used for analysis.
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in ESS Total Score
The ESS provides individuals with 8 different situations of daily life and asks them how likely they are to fall asleep in those situations (scored 0 to 3) and to try to imagine their likelihood of dozing even if they have not actually been in the identical situation; the scores are summed to give an overall score of 0 to 24. Higher scores indicate stronger subjective daytime sleepiness. A negative change from baseline indicates an improvement. The linear mixed effects model for repeated measures (MMRM) was used for analysis.
Time frame: Baseline, Week 12
Weekly Cataplexy Rate (WCR) at Week 12
Participants completed a daily participant-reported cataplexy diary to record self-reported episodes of cataplexy attacks. WCR = (total number of cataplexy attacks over a number of non-missing diary days for a given period/number of non-missing diary days in that period) \* 7. The generalized estimating equations (GEE) model was used for analysis. Reported here is the estimated mean of incidence rate with a 95 percent (%) confidence interval (CI).
Time frame: Week 12
Change From Baseline to Week 12 in Mean Number of Lapses on the Psychomotor Vigilance Test (PVT)
The PVT is a simple reaction performance task that aims to measure sustained attention. The mean number of lapses (delayed responses to a visual cue from intraday sessions) from the two 10-minute intraday sessions was used as a measure of objective sustained attention. A negative change from baseline indicates an improvement. A constrained Longitudinal Data Analysis (cLDA) model was used to analyze the mean number of lapses and to estimate change from baseline at each visit.
Time frame: Baseline, Week 12
Proportion of Participants With Improved Patient Global Impression of Change (PGI-C) Score at Week 12
The PGI-C is a participant self-rated scale to assess change in daytime sleepiness and overall narcolepsy symptoms. The PGI-C includes 7 items being scored from 1 (best outcome) to 7 (worst outcome) with 4 being no change. Responders were the participants reporting "1=very much improved" or "2=much improved" on PGI-C. Responder rate (proportion of participants who were responders) was estimated using a GEE model.
Time frame: Week 12
Change From Baseline to Week 12 in Narcolepsy Severity Scale for Clinical Trials (NSS-CT) Total Score
The NSS-CT is a 15-item self-administered questionnaire that assesses the severity and consequences of the 5 major narcolepsy symptoms such as daytime sleepiness, cataplexy, hallucinations, sleep paralysis, and disturbed nighttime sleep (DNS) with a total score range of 0 to 57 (sum of 6 items that assess symptoms severity are rated using a six-point Likert scale \[0-5\] and 9 items that describe the symptom effect on daily life are rated using a four-point Likert scale \[0-3\]). Higher total scores mean a worse outcome. A negative change from baseline indicates an improvement. The linear MMRM was used for analysis.
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in Functional Impacts of Narcolepsy Instrument (FINI) Domain Scores
The FINI measures the functional impacts of narcolepsy across 6 domains Tiredness (items 1-7), Cognitive Functioning (items 8-12), Cataplexy (items 13-17), Social Activities (items 18-21), Everyday Activities (items 22-25), and Everyday Responsibilities (items 26-28). Each item asks about the impact that narcolepsy has had on their daily functioning during the past 7 days, and is scored from 0 to 4, where 0 indicates the best health and 4 the worst. An average score is calculated for each domain and then standardized to a 0-100 scale, where 0 indicates the best health and 100 the worst health. Standardized score = average score/4 × 100. A negative change from baseline indicates and improvement. The linear MMRM was used for analysis.
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in Short Form-36 Survey (SF-36) Mental and Physical Component Scores
The SF-36 is a 36-item, participant-reported survey of participant health that assesses the quality of life and includes both physical and mental components. It consists of 8 scaled scores (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health), which contribute variably to the physical and mental component summary scores. The component summary is scored based on a normal value of 50 based on US population average, with a normative range considered from 45-55. The lower the score the more disability. A positive change from baseline indicates an improvement, and a change greater than 3 points is considered minimally clinically meaningful. The linear MMRM was used for analysis.
Time frame: Baseline, Week 12
Number of Participants With At Least One Treatment-Emergent Adverse Event (TEAE)
An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product. A TEAE is defined as any event emerging or manifesting at or after the initiation of treatment with a study intervention or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the study intervention or medicinal product.
Time frame: Up to 16 weeks
Participants took part in the study at various investigative sites globally from 08 October 2024 to 04 June 2025.
| Milestone | Placebo | Oveporexton |
|---|---|---|
| Started | 35 | 70 |
| Completed | 34 | 66 |
| Not completed | 1 | 4 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Reason not specified | 0 | 1 |
The MWT evaluates a person's ability to remain awake under soporific conditions for a defined period of time. Because there is no biological measure of wakefulness, wakefulness is measured indirectly by the inability or delayed tendency to fall asleep. This tendency to fall asleep is measured via electroencephalography-derived sleep latency in the MWT. The MWT consists of four 40-minute sessions (trials) done 2 hours apart. Sleep latency in each session was recorded. Participants were required to stay awake in between the four sessions. A positive change from baseline indicates an improvement. The linear MMRM was used for analysis.
| minutes | Placebo | Oveporexton |
|---|---|---|
| Change From Baseline to Week 12 in Mean Sleep Latency From the Maintenance of Wakefulness Test (MWT) Wake Trials | -1.01 ± 1.529 | 19.09 ± 1.254 |
The ESS provides individuals with 8 different situations of daily life and asks them how likely they are to fall asleep in those situations (scored 0 to 3) and to try to imagine their likelihood of dozing even if they have not actually been in the identical situation; the scores are summed to give an overall score of 0 to 24. Higher scores indicate stronger subjective daytime sleepiness. A negative change from baseline indicates an improvement. The linear mixed effects model for repeated measures (MMRM) was used for analysis.
| score on a scale | Placebo | Oveporexton |
|---|---|---|
| Change From Baseline to Week 12 in ESS Total Score | -1.57 ± 0.676 | -11.10 ± 0.550 |
Participants completed a daily participant-reported cataplexy diary to record self-reported episodes of cataplexy attacks. WCR = (total number of cataplexy attacks over a number of non-missing diary days for a given period/number of non-missing diary days in that period) \* 7. The generalized estimating equations (GEE) model was used for analysis. Reported here is the estimated mean of incidence rate with a 95 percent (%) confidence interval (CI).
| cataplexy attacks per week | Placebo | Oveporexton |
|---|---|---|
| Weekly Cataplexy Rate (WCR) at Week 12 | 24.43 (16.83 to 35.46) | 6.12 (4.44 to 8.42) |
The PVT is a simple reaction performance task that aims to measure sustained attention. The mean number of lapses (delayed responses to a visual cue from intraday sessions) from the two 10-minute intraday sessions was used as a measure of objective sustained attention. A negative change from baseline indicates an improvement. A constrained Longitudinal Data Analysis (cLDA) model was used to analyze the mean number of lapses and to estimate change from baseline at each visit.
| number of lapses | Placebo | Oveporexton |
|---|---|---|
| Change From Baseline to Week 12 in Mean Number of Lapses on the Psychomotor Vigilance Test (PVT) | 3.36 (-0.17 to 6.89) | -5.46 (-7.45 to -3.46) |
The PGI-C is a participant self-rated scale to assess change in daytime sleepiness and overall narcolepsy symptoms. The PGI-C includes 7 items being scored from 1 (best outcome) to 7 (worst outcome) with 4 being no change. Responders were the participants reporting "1=very much improved" or "2=much improved" on PGI-C. Responder rate (proportion of participants who were responders) was estimated using a GEE model.
| proportion of participants | Placebo | Oveporexton |
|---|---|---|
| Proportion of Participants With Improved Patient Global Impression of Change (PGI-C) Score at Week 12 | 0.15 (0.02 to 0.27) | 0.90 (0.82 to 0.97) |
The NSS-CT is a 15-item self-administered questionnaire that assesses the severity and consequences of the 5 major narcolepsy symptoms such as daytime sleepiness, cataplexy, hallucinations, sleep paralysis, and disturbed nighttime sleep (DNS) with a total score range of 0 to 57 (sum of 6 items that assess symptoms severity are rated using a six-point Likert scale \[0-5\] and 9 items that describe the symptom effect on daily life are rated using a four-point Likert scale \[0-3\]). Higher total scores mean a worse outcome. A negative change from baseline indicates an improvement. The linear MMRM was used for analysis.
| score on a scale | Placebo | Oveporexton |
|---|---|---|
| Change From Baseline to Week 12 in Narcolepsy Severity Scale for Clinical Trials (NSS-CT) Total Score | -3.04 ± 1.367 | -21.15 ± 1.090 |
The FINI measures the functional impacts of narcolepsy across 6 domains Tiredness (items 1-7), Cognitive Functioning (items 8-12), Cataplexy (items 13-17), Social Activities (items 18-21), Everyday Activities (items 22-25), and Everyday Responsibilities (items 26-28). Each item asks about the impact that narcolepsy has had on their daily functioning during the past 7 days, and is scored from 0 to 4, where 0 indicates the best health and 4 the worst. An average score is calculated for each domain and then standardized to a 0-100 scale, where 0 indicates the best health and 100 the worst health. Standardized score = average score/4 × 100. A negative change from baseline indicates and improvement. The linear MMRM was used for analysis.
| score on a scale | Placebo | Oveporexton |
|---|---|---|
| Tiredness: Week 12 | -4.32 ± 3.410 | -45.09 ± 2.822 |
| Cognitive Functioning: Week 12 | -3.56 ± 3.586 | -33.74 ± 2.835 |
| Cataplexy: Week 12 | -5.53 ± 3.028 | -24.63 ± 2.484 |
| Social Activities: Week 12 | 0.05 ± 3.769 | -36.06 ± 3.009 |
| Everyday Activities: Week 12 | -6.66 ± 3.476 | -47.84 ± 2.814 |
| Everyday Responsibilities: Week 12 | -2.98 ± 4.145 | -42.20 ± 3.363 |
The SF-36 is a 36-item, participant-reported survey of participant health that assesses the quality of life and includes both physical and mental components. It consists of 8 scaled scores (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health), which contribute variably to the physical and mental component summary scores. The component summary is scored based on a normal value of 50 based on US population average, with a normative range considered from 45-55. The lower the score the more disability. A positive change from baseline indicates an improvement, and a change greater than 3 points is considered minimally clinically meaningful. The linear MMRM was used for analysis.
| score on a scale | Placebo | Oveporexton |
|---|---|---|
| Physical Component Summary (PCS): Week 12 | -0.30 ± 1.049 | 4.71 ± 0.854 |
| Mental Component Summary (MCS): Week 12 | -0.86 ± 1.431 | 8.45 ± 1.165 |
An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product. A TEAE is defined as any event emerging or manifesting at or after the initiation of treatment with a study intervention or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the study intervention or medicinal product.
| Participants | Placebo | Oveporexton |
|---|---|---|
| Number of Participants With At Least One Treatment-Emergent Adverse Event (TEAE) | 15 | 60 |
Collected over Up to 16 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/35 (0%) | 0/35 (0%) | 6/35 (17.1%) |
| Oveporexton | 0/70 (0%) | 0/70 (0%) | 56/70 (80%) |
| Event | Placebo | Oveporexton |
|---|---|---|
| PollakiuriaRenal and urinary disorders | 1/35 | 43/70 |
| InsomniaPsychiatric disorders | 1/35 | 40/70 |
| Micturition urgencyRenal and urinary disorders | 0/35 | 10/70 |
| Salivary hypersecretionGastrointestinal disorders | 0/35 | 5/70 |
| GastroenteritisInfections and infestations | 2/35 | 2/70 |
| HeadacheNervous system disorders | 2/35 | 3/70 |
| RashSkin and subcutaneous tissue disorders | 0/35 | 4/70 |
| Upper respiratory tract infectionInfections and infestations | 2/35 | 3/70 |
The Full Analysis Set (FAS) consisted of all participants who were randomized.
| Age, Continuous(years) | Placebo | Oveporexton | Total |
|---|---|---|---|
| Mean | 34.0 ± 13.14 | 29.1 ± 9.62 | 30.7 ± 11.1 |
| Sex: Female, Male(Participants) | Placebo | Oveporexton | Total |
|---|---|---|---|
| Female | 13 | 37 | 50 |
| Male | 22 | 33 | 55 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Oveporexton | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 26 | 42 | 68 |
| Unknown or Not Reported | 9 | 28 | 37 |
| Race (NIH/OMB)(Participants) | Placebo | Oveporexton | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 7 | 14 | 21 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 19 | 28 | 47 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 9 | 28 | 37 |
| Mean Sleep Latency from the Maintenance of Wakefulness Test (MWT)(minutes) | Placebo | Oveporexton | Total |
|---|---|---|---|
| Mean | 4.1 ± 4.93 | 4.8 ± 4.90 | 4.5 ± 4.9 |
| Epworth Sleepiness Scale (ESS) Total Score(score on a scale) | Placebo | Oveporexton | Total |
|---|---|---|---|
| Mean | 17.9 ± 2.95 | 17.3 ± 3.38 | 17.5 ± 3.24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Oct 2024 to primary completion in Jun 2025, 7 months.
Results were first posted in Jul 2026, 1 year 1 month after primary completion.
Of 14 phase 3 interventional studies under Narcolepsy, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 40. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oveporexton